Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cabaletta Bio, Inc.CABA · Entity 5418 | President, Science & Tech. | March 02, 2026 | March 03, 2026 |
| Instil Bio, Inc.TIL · Entity 7177 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cabaletta Bio, Inc.
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2036-03-01 | Direct | 225,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 225,000 · Balance 225,000 F1: 25% of the shares underlying this option shall vest and become exercisable on March 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option shall vest and become exercisable on March 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
Instil Bio, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.93 · Expires 2036-06-10 | Direct | 6,500 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 6,500 · Balance 6,500 F1: The option will vest in 12 substantially equal monthly installments commencing on July 11, 2026, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the "Plan") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 12 substantially equal monthly installments commencing on July 11, 2026, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the "Plan") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jan 11, 2024 01:10 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $11.18 | $0.00 |
DisclosureSEC source: 0001789769-24-000011 · wk-form4_1704935440.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:10 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000899243-23-013455 · doc4.xml · derivative · entry 3 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,756 Underlying: Common Stock · 22,000 shares Expires 2028-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:10 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | SaleCommon Stock | 22,000 | $11.81 | $259,833.20 |
DisclosureSEC source: 0000899243-23-013455 · doc4.xml · nonDerivative · entry 2 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 - $12.27. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:10 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | Exercise / conversionCommon Stock | 22,000 | $1.01 | $22,220.00 |
DisclosureSEC source: 0000899243-23-013455 · doc4.xml · nonDerivative · entry 1 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person. Read SEC document |
| January 18, 2023 Filed Jan 28, 2023 01:50 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 176,000 | $0.00 Strike: $11.09 | $0.00 |
DisclosureSEC source: 0000899243-23-002910 · doc4.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 18, 2024, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 01:50 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | PurchaseCommon Stock | 20,000 | $0.99 | $19,894.00 |
DisclosureSEC source: 0000899243-22-033780 · doc4.xml · nonDerivative · entry 1 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $0.9894 to $0.9947, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 20, 2022 Filed May 25, 2022 22:01 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001789769-22-000049 · wf-form4_165351607627422.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments commencing on June 20, 2022, subject to the Report Person's continued service as a director through the vesting date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 00:53 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0000899243-22-002508 · doc4.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 00:47 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022470 · doc4.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2031-03-18 F1 · derivative.exercise_date: The option will vest in 36 equal monthly installments commencing on April 18, 2021, subject to the Report Person's continued service as a director through the vesting date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 02:46 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0000899243-21-009234 · doc4.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · EVP, Science & Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: This option vests over four years, with 25% vesting on March 1, 2022 and the remaining shares vesting in 12 equal quarterly installments thereafter. Read SEC document |
| October 24, 2019 Filed Oct 29, 2019 00:43 UTC | Cabaletta Bio, Inc. CABA · Entity 5418 | GrantStock Option (Right to Buy) · Derivative | 29,908 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000899243-19-026020 · doc4.xml · derivative · entry 1 Binder Gwendolyn · CIK 0001791742 · EVP, Science & Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,908 Underlying: Common Stock · 29,908 shares Expires 2029-10-23 F1 · derivative.exercise_date: This option vests over four years, with 25% vesting on October 24, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.